Study to Assess Safety and Efficacy of Multiple Doses of IONIS-FB-LRX

A Phase 2, Randomized, Placebo-Controlled, Double-Masked Study to Assess Safety and Efficacy of Multiple Doses of IONIS-FB-LRX, an Antisense Inhibitor of Complement Factor B, in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration (AMD)

Purpose of Study

The purpose of this study is to see if the new study drug reduces the amount of Factor B (a protein made in the liver and found in the eye) and if this will slow the progression of geographic Atrophy in persons who have Age Related Macular Degeneration.

Basic Eligibility Criteria

  • Diagnosis of Geographic Atrophy, which occurs as a result of Age Related Macular Degeneration

How to Contact Us

Principal Investigator: Shree Kurup, MD
Study Coordinator: Leslie Castaneda | 216-844-2032

Back to Top